Targeted Oncology1h
ARANOTE Features Significant rPFS Benefit of Darolutamide/ADT in mHSPC
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...
Targeted Oncology3h
A New AI Tool Assists Pathologists in Assessing HER2 0 vs 1+ in Breast Cancer
Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...
Targeted Oncology5h
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
Targeted Oncology23h
Patient-Centered Care in Myelofibrosis: Managing Expectations and Quality-of-Life Outcomes
Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with ...
Targeted Oncology23h
Myelofibrosis Disease Biology: From Molecular Mechanisms to Clinical Phenotypes and Therapeutic Targets
Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations ...
Targeted Oncology23h
Advancing Cancer Care: NYU Langone’s Molecular Oncology Program
Alec Kimmelman, MD, PhD, and Shridar Ganesan, MD, PhD, discuss the institution's new molecular oncology program.